ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2549

Can Biomarkers Provide An Objective Standard Against Which To Assess Lupus Clinical Endpoint Measures?

Aikaterini Thanou1, Melissa E. Munroe2, Stan Kamp3, Joel M. Guthridge4, Judith A. James5 and Joan T. Merrill6, 1Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: biomarkers and outcome measures, IL-6

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications

Session Type: Abstract Submissions (ACR)

Background/Purpose: Despite the heterogeneity of SLE, specific pathways of immune dysregulation characterize significant subsets of patients. We examined cytokines reflecting IL6-TH17 pathology in lupus as an objective standard to test performance of clinical outcome measures.

Methods: 91 patients, all with active disease at baseline (SLEDAI >/= 6) participated in two visits at which BILAG and SLEDAI were prospectively scored. A clinician retrospectively assessed the second visit as overall worse, the same, or improved. Cytokines were measured by xmap multiplex bead-based assay.

Results: Using physician-rated improvement (PRI), 68 patients improved and 23 were same or worse at follow up. Cytokine changes were evaluated in patients who did or did not meet response criteria of PRI, SRI (SLE Responder Index) and BICLA (BILAG-based Composite Lupus Assessment). Of patients with detectable IL6 at baseline and/or follow up (IL6+) (n=51), those who improved by PRI, SRI or BICLA had a significant drop in IL6, not observed in patients who did not improve (Table 1). IL21 and IL23 decreased in those who improved by PRI, but did not track with SRI or BICLA. IL17 was only detected in 3 patients and could not be evaluated.

 

Table 1. P values of cytokine changes in patients with detectable cytokine levels at baseline and/or follow up

IL6 (n=51)

PRI

SRI

BICLA

IL21 (n=57)

PRI

SRI

BICLA

IL23 (n=24)

PRI

SRI

BICLA

Endpoint met

n=39 p=0.010

n=42 p=0.032

n=32 p=0.021

Endpoint met

n=45 p=0.008

n=43 p=0.042

n=41 p=0.084

Endpoint met

n=18 p=0.048

n=16 p=0.252

n=18 p=0.08

Endpoint not met

n=12 p=0.569

n=9 p=0.82

n=19 p=0.141

Endpoint not met

n=12 p=0.266

n=14 p=0.017

n=16 p=0.006

Endpoint not met

n=6 p=0.625

n=8 p=0.195

n=6 p=0.313

IL21 and IL23 were detectable when IL6 was, both at baseline (p<0.001 and p=0.002 respectively) and at follow up (p=0.032 and p=0.006). In IL6+/IL21+ (double positive) patients (n=35), IL21 tracked well with IL6 (p=0.0028), driven by the patients who improved by PRI (n=26) (p=0085).

In IL6+ patients the PRI was tested as a standard to compare performance of SRI and BICLA (sensitivities 94.9% and 74.4%, specificities 58.3% and 75%). Using decrease in IL6 as an objective standard of improvement, sensitivities of SRI vs BICLA were 85.2% vs 66.7% and specificities were 35.9% vs 39.1%.

Conclusion: Decreases in IL6, IL21 and IL23 reflected improvements by SRI, BICLA and clinical judgement. IL21 and IL23 were detectable when IL6 was, consistent with expected relatedness in an IL6-TH17 pathway. The SRI was more sensitive than and as specific as the BICLA in detecting objective biologic change in this subset of IL6 producing patients. Low specificities underscore the multiple pathways of lupus pathology, but we speculate that a range of predictable cytokine changes in definable patient subsets could be formulated into objective standards for testing clinical outcome instruments.

 

 

 

 

 


Disclosure:

A. Thanou,
None;

M. E. Munroe,
None;

S. Kamp,
None;

J. M. Guthridge,
None;

J. A. James,
None;

J. T. Merrill,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-biomarkers-provide-an-objective-standard-against-which-to-assess-lupus-clinical-endpoint-measures/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology